Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. WHO/FRH/FPP, Geneva1996
- Statement by the International Medical Advisory Panel, 1989: 1-5 (November) Statement on breast feeding, fertility, and post-partum contraception.
- Pharmacokinetics and bioavailability of ST-1435 administered by different routes.Contraception. 1993; 48: 548-556
- The progestin ST-1435 rapid metabolism in man.Contraception. 1994; 50: 275-289
- Long-term contraception with a single implant of the progestin ST-1435.Fertil Steril. 1981; 36: 737-740
- Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435.Contraception. 1981; 23: 63-75
- Contraception with subdermal implants releasing the progestin ST-1435.Contraception. 1992; 45: 49-55
- Clinical trial with Nestorone™ subdermal contraceptive implant.Contraception. 1995; 51: 33-38
- Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Helsinki, Finland1986 Contraceptive action of a synthetic progestin, ST-1435 (academic dissertation).
- Pituitary, and ovarian function during contraception with one s.c. implant releasing a progestin, ST-1435.Contraception. 1982; 25: 299-306
- Contraception-dependent mechanisms of ovulation inhibition by the progestin ST-1435.Fertil Steril. 1985; 44: 19-24
- Ovarian function during use of Nestorone® subdermal implants.Contraception. 2000; 61: 199-204
- Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.Contraception. 1985; 31: 123-130
- Milk, and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.Contraception. 1990; 43: 555-562
- Nelson W.E. Textbook of Pediatrics. 8th ed. WB Saunders Company, Philadelphia1964
- The PHREG procedure, preliminary documentation. SAS Institute Inc, Cary, NC1991
- John Wiley & Sons, New York1981: 24-36 Statistical methods for rates, and proportions.
- A microcomputer software for analysis of menstrual diaries.Contraception. 1988; 38: 157-163
- John Wiley & Sons, New York1972: 115,125, 131 Nonparametric statistical methods.
- SAS Institute Inc, Cary, NC1987 SAS/STAT™ guide for personal computers. 6th ed.
- Progestogen-only contraceptives during lactation.Contraception. 1994; 50: 35-53
- Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, NorplantR implants, and Copper T 380-A intrauterine devices.Contraception. 1997; 56: 223-232
- Fertility regulation in nursing women. IV. Long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and infant growth.Contraception. 1983; 27: 13-25
- Effects of hormonal contraceptives on breast milk composition and infant growth.Stud Fam Plann. 1988; 6: 361-369
- Contraceptives for lactating women.Contraception. 1997; 55: 225-232
- Exposure to contraceptive hormones through breast milk—are there long-term health and behavioral consequences?.Int J Gynaecol Obstet. 1987; 25: 47-55
- Use of a single implant of Elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women.Contraception. 1999; 59: 115-122
- The place of progesterone in human contraception.J Steroid Biochem. 1987; 27: 991-994
- Transfer of contraceptive steroids in milk of women using long-acting gestagens.Contraception. 1982; 25: 321-331
- Performance of the Copper T-380 A intrauterine device in breastfeeding women.Contraception. 1989; 39: 603-618